Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06841679 · ClinicalTrials.gov registry record · Phase 2
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase 2 study of Gastric or Gastroesophageal Junction Adenocarcinoma, sponsored by Beijing Biostar Pharmaceuticals Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 778
- Enrollment target
- 10
- Study locations
NCT06841679: Recruiting Phase 2 study of Gastric or Gastroesophageal Junction Adenocarcinoma, sponsored by Beijing Biostar Pharmaceuticals Co..
NCT06841679 is a Phase 2 study of Gastric or Gastroesophageal Junction Adenocarcinoma that is actively recruiting participants, run by Beijing Biostar Pharmaceuticals Co.. The registered enrollment target is 778 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (485% higher). The trial reports 10 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06841679, a Phase 2 study of Gastric or Gastroesophageal Junction Adenocarcinoma, is actively recruiting participants, sponsored by Beijing Biostar Pharmaceuticals Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 778 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a multi-national, open-label, randomized, seamless phase II/III clinical study of UTD2 combined with fluoropyrimidine- and platinum-containing therapy to evaluate the efficacy and safety in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma untreated with systemic treatment in advanced setting.
Primary Outcome
dose limiting toxicity (DLT), defined as any toxicity meeting the criteria outlined in the protocol during Cycle 1 in a 21-days cycle
Conditions Studied
Interventions
- DRUG Oxaliplatin
- DRUG Utidelone Capsule
- DRUG Fluoropyrimidine- and Platinum-containing Therapy
Study Locations (10)
Other
- AnYang Tumor Hospital - Anyang
- Sun Yat-sen University Cancer Center - Guangzhou
- Jinan Municipal Central Hospital - Jinan
- Shandong First Medical University Affiliated Tumor Hospital - Jinan
- Liaoning Cancer Hospital - Shenyang
- Shanxi Cancer Hospital - Taiyuan
- Tianjin Medical University Cancer Institute & Hospital - Tianjin
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology - Wuhan
- Henan Cancer Hospital - Zhengzhou
Florida
- Bioresearch Partner - Hialeah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 778 participants |
| Start Date | 2025-08-28 |
| Est. Completion | 2030-09-01 |
| Phase | Phase 2 |
What NCT06841679 shows while recruiting
NCT06841679 is an interventional study that assigns participants to a tested intervention. The registered 778 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (485% higher).
The record links to 1 condition, with Gastric or Gastroesophageal Junction Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Oxaliplatin is the first listed.
NCT06841679 lists 10 locations in 2 states (Other, Florida).
Frequently Asked Questions
What is clinical trial NCT06841679 about?
NCT06841679 is a clinical study titled "Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma". This is a multi-national, open-label, randomized, seamless phase II/III clinical study of UTD2 combined with fluoropyrimidine- and platinum-containing therapy to evaluate the efficacy and safety in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma untre...
What is the current status of trial NCT06841679?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 778 participants. The study started on 2025-08-28. Estimated completion is 2030-09-01.
What conditions does trial NCT06841679 study?
This clinical trial studies the following conditions: Gastric or Gastroesophageal Junction Adenocarcinoma.
What interventions are being tested in trial NCT06841679?
The interventions under investigation include: Oxaliplatin (DRUG), Utidelone Capsule (DRUG), Fluoropyrimidine- and Platinum-containing Therapy (DRUG).
Who is sponsoring clinical trial NCT06841679?
This trial is sponsored by Beijing Biostar Pharmaceuticals Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06841679 being conducted?
This trial has 10 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric or Gastroesophageal Junction Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06841679's enrollment target sits among peer trials
778 41st of 2000 higher than 1,960 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
RECRUITING · Phase 1
-
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05642611 · 777 participants · Phase 3
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
- NCT05046613 · 780 participants
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
- NCT05100862 · 780 participants · Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- NCT05513872 · 780 participants · Phase 1
Overcoming Nicotine Dependence to Enable Quitting
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI